272 related articles for article (PubMed ID: 32700461)
21. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
22. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension.
Nowak RJ; Breiner A; Bril V; Allen JA; Khan S; Levine T; Jacobs DH; Sahagian G; Siddiqi ZA; Xu J; Macias WL; Benatar M;
Ann Clin Transl Neurol; 2024 Jan; 11(1):194-206. PubMed ID: 38062618
[TBL] [Abstract][Full Text] [Related]
24. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
Greenwood GT; Lynch Z
Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
[TBL] [Abstract][Full Text] [Related]
26. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
[TBL] [Abstract][Full Text] [Related]
28. Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
Mimori M; Komatsu T; Maku T; Mitsumura H; Iguchi Y
Neurol Sci; 2022 Jul; 43(7):4081-4083. PubMed ID: 35364770
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF; Bresch S; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Lowcock R; Vanderkelen M; Leite MI;
Lancet Neurol; 2023 May; 22(5):395-406. PubMed ID: 37059508
[TBL] [Abstract][Full Text] [Related]
30. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
Xiao H; Wu K; Liang X; Li R; Lai KP
Front Immunol; 2021; 12():715036. PubMed ID: 34456922
[TBL] [Abstract][Full Text] [Related]
31. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
32. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
Vissing J; O'Brien F; Wang JJ; Howard JF
Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
[No Abstract] [Full Text] [Related]
33. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.
Oyama M; Okada K; Masuda M; Shimizu Y; Yokoyama K; Uzawa A; Kawaguchi N; Ikeguchi R; Hoshino Y; Hatano T; Ozawa Y; Nakahara J; Aizawa H; Kitagawa K; Hattori N; Kuwabara S; Murai H; Suzuki S
Ther Adv Neurol Disord; 2020; 13():1756286420904207. PubMed ID: 32215054
[TBL] [Abstract][Full Text] [Related]
34. Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series.
Kang SA; Sweeney M; Govindarajan R
J Clin Neuromuscul Dis; 2022 Jun; 23(4):210-218. PubMed ID: 35608645
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V; Drużdż A; Grosskreutz J; Habib AA; Mantegazza R; Sacconi S; Utsugisawa K; Vissing J; Vu T; Boehnlein M; Bozorg A; Gayfieva M; Greve B; Woltering F; Kaminski HJ;
Lancet Neurol; 2023 May; 22(5):383-394. PubMed ID: 37059507
[TBL] [Abstract][Full Text] [Related]
36. Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
Ohnari K; Hashimoto T; Iwanaka Y; Ohnari K; Adachi H; Okada K
J Neurol; 2024 May; 271(5):2902-2905. PubMed ID: 38393426
[No Abstract] [Full Text] [Related]
37. Eculizumab for the treatment of myasthenia gravis.
Mantegazza R; Cavalcante P
Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
[TBL] [Abstract][Full Text] [Related]
38. Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series.
Levine TD
Am J Case Rep; 2019 Jul; 20():965-970. PubMed ID: 31278249
[TBL] [Abstract][Full Text] [Related]
39. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
40. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Suh J; Clarke V; Amato AA; Guidon AC
Muscle Nerve; 2022 Sep; 66(3):348-353. PubMed ID: 35684980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
